WO2024111676A1 - Système d'injection de solution chimique - Google Patents

Système d'injection de solution chimique Download PDF

Info

Publication number
WO2024111676A1
WO2024111676A1 PCT/JP2023/042433 JP2023042433W WO2024111676A1 WO 2024111676 A1 WO2024111676 A1 WO 2024111676A1 JP 2023042433 W JP2023042433 W JP 2023042433W WO 2024111676 A1 WO2024111676 A1 WO 2024111676A1
Authority
WO
WIPO (PCT)
Prior art keywords
syringe
injection
liquid
screen
display
Prior art date
Application number
PCT/JP2023/042433
Other languages
English (en)
Japanese (ja)
Inventor
茂 根本
由美子 吹越
Original Assignee
株式会社根本杏林堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社根本杏林堂 filed Critical 株式会社根本杏林堂
Publication of WO2024111676A1 publication Critical patent/WO2024111676A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body

Definitions

  • the present invention relates to a drug injection system.
  • Chemical fluid injection devices are often used to inject medicinal fluid into subjects.
  • Many chemical fluid injection devices have an injection head to which a syringe is removably attached, from the viewpoint of facilitating injection at a desired injection rate, and are configured to inject the medicinal fluid filled in the syringe via a chemical fluid circuit that fluidly connects the syringe attached to the injection head to the subject.
  • a syringe is used only once, but it may be used multiple times by refilling the syringe with the liquid from the liquid bottle while the syringe is attached to the injection head.
  • the liquid circuit disclosed in Patent Document 1 is known as an example of a liquid circuit that can be used in this case.
  • the liquid circuit disclosed in Patent Document 1 includes a syringe line connected to the syringe, a liquid line connected to a liquid container, a subject line connected to a subject, and a baseline to which each of these lines is connected.
  • a valve device is provided at an appropriate position in the liquid circuit so as to allow only the flow of liquid from the syringe line to the subject line when injecting the liquid, and to allow only the flow of liquid from the liquid line to the syringe line when filling the liquid.
  • the baseline is configured to be separable via a one-way valve downstream of the connection with the liquid line, and the downstream part of the baseline connected to the subject line can be replaced each time the liquid is injected.
  • the upstream part of the liquid medicine circuit can be used as a multi-use part that can repeatedly inject and fill the liquid medicine while still attached to the syringe, and the downstream part of the liquid medicine circuit can be used as a single-use part that is replaced each time the liquid medicine is injected.
  • Patent document 1 International Publication No. 2014/104338
  • the liquid medicine circuit described in Patent Document 1 has a relatively complicated configuration, and it is important to consider how to incorporate such a liquid medicine circuit into a system that includes an injection head and a syringe.
  • the direction is described when the syringe is attached (held). Specifically, “front” refers to the side of the syringe in the longitudinal direction where the nozzle for injecting the liquid is provided, and the opposite side is described as “rear.”” “Down” refers to the direction in which the syringe is moved when attached to the liquid injector, and “up” refers to the opposite direction. “Right” and “left” refer to directions perpendicular to the front-back and up-down directions.
  • the state of the drug injection system can be easily understood.
  • FIG. 1 is a schematic diagram of a medical imaging system according to an embodiment of the present invention
  • FIG. 2 is a schematic diagram of the chemical liquid circuit shown in FIG. 1
  • 3 is a perspective view of one embodiment of a flow path opening/closing valve used in the chemical liquid circuit shown in FIG. 2.
  • FIG. 2B is an exploded perspective view of the flow passage opening/closing valve shown in FIG. 2A.
  • 2B is a cross-sectional view of the flow passage opening/closing valve shown in FIG. 2A.
  • FIG. 2 is a perspective view showing the injection head shown in FIG. 1 together with its peripheral devices.
  • FIG. 2 is a perspective view of the injection head shown in FIG. 1 .
  • 4B is a perspective view of the injection head shown in FIG.
  • FIG. 4A is a perspective view of the injection head shown in FIG. 4A with the syringe cover open and the syringe before attachment.
  • FIG. FIG. 4B is a perspective view of the injection head shown in FIG. 4A with the syringe cover and a portion of the housing removed to expose the linear actuator.
  • FIG. 4B is a side view of the injection head shown in FIG. 4A.
  • 4B is a plan view of a flow path opening/closing valve holding unit of the injection head shown in FIG. 4A.
  • 4F is a plan view of the flow path opening/closing valve holding unit shown in FIG. 4E in a state in which the flow path opening/closing valve is removed.
  • FIG. FIG. 4B is an exploded perspective view of the syringe shown in FIG. 4A.
  • FIG. 6 is a rear perspective view of the syringe shown in FIG. 5 .
  • 6 is a cross-sectional view of the rear end side of the syringe barrel shown in FIG. 5 .
  • FIG. 6 is a rear perspective view of the plunger shown in FIG. 5 .
  • FIG. 6 is a rear view of the plunger shown in FIG. 5 .
  • FIG. 6 is a cross-sectional view of the plunger shown in FIG. 5 with a gasket attached.
  • 6 is a cross-sectional view showing another embodiment of the plunger shown in FIG. 5 with a gasket attached.
  • FIG. 4D is a cross-sectional view of the syringe support assembly and linear actuator shown in FIG. 4C in relation to the syringe.
  • FIG. 4D is a cross-sectional view of the syringe support assembly and linear actuator shown in FIG. 4C in relation to the syringe.
  • FIG. 6B is a perspective view of a main portion of the rod and presser shown in FIG. 6A.
  • 4B is an enlarged perspective view of the syringe support assembly and its periphery of the injection head shown in FIG. 4A with the syringe cover removed.
  • FIG. 6B is a perspective view of the syringe retainer shown in FIG. 6A.
  • 1 is a cross-sectional view of a syringe support assembly with a syringe attached thereto;
  • FIG. 11A and 11B are cross-sectional views illustrating the operation of a syringe by a linear actuator.
  • 11A and 11B are cross-sectional views illustrating the operation of a syringe by a linear actuator.
  • FIG. 11A and 11B are cross-sectional views illustrating the operation of a syringe by a linear actuator.
  • 13 is a diagram illustrating the dimensional relationship between a circumferential groove of a presser and an inner protrusion of an engaging claw of a plunger.
  • FIG. FIG. 2 is a perspective view of a main portion of an injection head with a syringe attached thereto, with the syringe cover removed.
  • FIG. 4 is a perspective view for explaining the container holder shown in FIG. 3 .
  • 10B is a perspective view showing the container holder shown in FIG. 10A with a holder cover removed.
  • FIG. FIG. 13 is a perspective view showing another embodiment of the container holder.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 14 is a diagram showing another form of the screen shown in FIG. 13 .
  • 13B is a diagram showing a screen displayed when a predetermined operation is performed on the screen shown in FIG. 13A.
  • FIG. FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • FIG. 13 is a diagram showing an example of a screen displayed on the console and/or the head display.
  • CT Compputed Tomography
  • MRI Magnetic Resonance Imaging
  • PET PET
  • FIG. 1 there is shown a schematic diagram of a medical imaging injection system according to an embodiment of the present invention, including a liquid injection device 10, a liquid circuit 30, and a medical imaging device 50.
  • the liquid injection device 10 has an injection head 10a and a console 10b.
  • the liquid circuit 30 fluidly connects the injection head 10a and a subject.
  • the liquid injection device 10 and the medical imaging device 50 can be connected to each other so that data can be transmitted and received between them.
  • the connection between the two may be a wired connection or a wireless connection.
  • the medical imaging device 50 has an imaging operation unit 52 that performs imaging operations and an imaging control unit 51 that controls the operation of the imaging operation unit 52, and can obtain medical images including tomographic images and/or three-dimensional images of a subject into which a liquid medicine has been injected by the liquid medicine injector 10.
  • the imaging operation unit 52 usually has a bed for the subject, an electromagnetic wave irradiation unit that irradiates electromagnetic waves into a predetermined space above the bed, etc.
  • the imaging control unit 51 controls the operation of the entire medical imaging device, such as determining imaging conditions and controlling the operation of the imaging operation unit 52 according to the determined imaging conditions.
  • the imaging control unit 51 can be configured to include a so-called microcomputer, and can have a CPU, ROM, RAM, and interfaces with other devices.
  • a computer program for controlling the medical imaging device 50 is implemented in the ROM.
  • the CPU controls the operation of each part of the medical imaging device 50 by executing various functions corresponding to this computer program.
  • the medical imaging device 50 is also connected to the console 10b of the liquid injection device 10 via the NCOM 17, which is a relay device that includes a communication protocol conversion function. Specifically, the imaging control unit 51 of the medical imaging device 50 and the injection control unit 11 of the console 10b are connected via the NCOM 17.
  • the medical imaging device 50 may further include a display device 54 such as a liquid crystal display capable of displaying imaging conditions and acquired medical images, and an input device 53 for inputting imaging conditions.
  • a display device 54 such as a liquid crystal display capable of displaying imaging conditions and acquired medical images
  • an input device 53 for inputting imaging conditions.
  • the input device 53 at least one type of known input device such as various buttons, a keyboard, and a mouse may be used.
  • At least a portion of the data used to determine the imaging conditions is input from the input device 53 and transmitted to the imaging control unit 51.
  • Data displayed on the display device 54 is transmitted from the imaging control unit 51.
  • a touch panel having a touch screen arranged as an input device on a display device which is a display device, may be used as the input device 53 and the display device 54.
  • a portion of the input device 53, the display device 54, and the imaging control unit 51 may be incorporated into a single housing as a console for the medical imaging device.
  • the drug injection device 10 is a device used to inject a drug solution filled in a syringe into the blood vessel of a subject via a drug solution circuit 30.
  • the syringe is detachably mounted on the injection head 10a, and at least one syringe drive mechanism for operating the plunger (or piston) of the syringe is built into the injection head 10a.
  • the injection head 10a is configured to be able to mount two syringes 20A, 20B so that two types of drug solutions, such as contrast medium and saline, can be injected separately or simultaneously, and has two syringe drive mechanisms for independently operating each of the syringes 20A, 20B.
  • the injection head 10a may be configured to have three or more syringes mounted thereon, have three or more syringe drive mechanisms corresponding to each mounted syringe, and be able to independently operate each syringe.
  • one of the three or more syringes may have a data carrier such as a barcode or two-dimensional code, and the injection head 10a may have a data reader that reads data from the data carrier.
  • the console 10b has an injection control unit 11, an input device 12, and a display device 13.
  • the injection control unit 11 controls the operation of the entire liquid injection device by determining injection conditions such as the injection amount and injection speed of the liquid using at least a portion of the data input from the input device 12, controlling the operation of the injection head 10a so that the liquid is injected according to the determined injection conditions, and controlling the display on the display device 13.
  • the injection control unit 11 can be configured to include a so-called microcomputer, and can have a CPU, ROM, RAM, and interfaces with other devices.
  • a computer program for controlling the liquid injection device 10 is implemented in the ROM.
  • the CPU can control the operation of each part of the liquid injection device 10 by executing various functions corresponding to this computer program.
  • the input device 12 is a device used to input data used by the injection control unit 11 to determine the injection conditions of the medicinal liquid.
  • the input device 12 at least one type of well-known input device such as various buttons, a keyboard, and a mouse can be used.
  • the data input from the input device 12 is transmitted to the injection control unit 11, and the data displayed on the display device 13 is transmitted from the injection control unit 11.
  • the display device 13 is controlled by the injection control unit 11, and displays data necessary for determining the injection conditions of the medicinal liquid, the injection protocol, the injection operation, various guidance messages, and various warnings.
  • An injection protocol indicates what type of medicinal liquid is to be injected, in what amount, and at what speed.
  • the injection speed may be constant or may change over time.
  • the injection protocol also includes information on the order in which the medicinal liquids are to be injected. Any known injection protocol can be used as the injection protocol.
  • a known procedure can also be used for setting the injection protocol, and the user can change the set injection protocol as desired.
  • An injection protocol may also include a maximum allowable injection pressure (pressure limit). When a pressure limit is set, the injection pressure is monitored during the injection operation, and the operation of the injection head 10a is controlled so that the injection pressure does not exceed the set pressure limit.
  • the display device 13 may be a known display device, such as a liquid crystal display device.
  • a touch panel having a touch screen arranged as an input device on a display device, which is a display device, may also be used as the input device 12 and the display device 13.
  • a part of the input device 12 may be provided separately from the console.
  • a hand switch 14 may be connected to the console 10b.
  • the hand switch 14 is connected to the injection control unit 11 of the console 10b.
  • the hand switch 14 has at least one operation button that is operated by the user, and is used to control the start and stop of the injection operation of the medicinal liquid by the injection head 10a.
  • the control of the injection operation by the hand switch 14 may be such that the injection operation of the medicinal liquid is performed only while the operation button is pressed, or that the injection operation is started when the operation button is pressed and stopped when the operation button is pressed again.
  • the console 10b may also be connected to a RIS (radiology information system) 16 via an EBOX 15, which is a relay device that includes a communication protocol conversion function.
  • the RIS 16 is connected to the injection control unit 11 of the console 10b.
  • the liquid fluid circuit 30 forms a liquid flow path connecting the syringe and the subject, and can have at least one tube, at least one connector, and at least one valve.
  • FIG. 2 One form of the liquid medicine circuit 30 that can be suitably used in the liquid medicine injector 10 shown in FIG. 1 is shown in FIG. 2.
  • the liquid medicine circuit 30 shown in FIG. 2 is connected to the syringes 20A and 20B, and is used when injecting the first liquid medicine and the second liquid medicine contained in each of the syringes 20A and 20B into a subject.
  • the liquid medicine circuit 30 can also connect the first container 40A and the second container 40B that contain the first liquid medicine and the second liquid medicine, respectively, and can aspirate the first liquid medicine and the second liquid medicine from the first container 40A and the second container 40B into each of the syringes 20A and 20B, respectively.
  • the first liquid medicine and the second liquid medicine are medical liquid medicines, and the following description will be given of the case where the first liquid medicine is a contrast medium and the second liquid medicine is physiological saline.
  • the drug solution circuit 30 has a first main line 301a connected to a syringe 20A containing a contrast medium, a second main line 302a connected to a syringe 20B containing saline, a first sub-line 301b connected to a first container 40A containing a contrast medium, a second sub-line 302b connected to a second container 40B containing saline, and a subject line 303 located downstream of the first main line 301a.
  • a “line” refers to a flow path through which a liquid flows, and includes various components through which the liquid flows (for example, various tubes, T-shaped tubes, various fluid connectors, various valves, mixing devices, etc.).
  • each line is shown for convenience of illustration, and the relative length of each line does not represent the relative length of the actual line.
  • the term "tube” used in the following explanation may be composed of a single tube member, or may be composed of a tube assembly in which multiple tube members are connected.
  • the first main line 301a has a tube as a main component, and further has, in order from the upstream side, a syringe connector 310a, a T-shaped tube 311a, a mixing device 312a, and a needleless valve 313a.
  • the syringe connector 310a is rotatably connected to the T-shaped tube 311a via a rotary joint, and the syringe 20A is detachably connected.
  • the mixing device 312a has two inlets and one outlet, and is configured to mix the liquids that flow in from the inlets and flow out from the outlet.
  • One of the two inlets of the mixing device 312a is connected to the second main line 302a, and the contrast medium and physiological saline are mixed by the mixing device 312a.
  • the mixing device 312a For example, the "SPIRAL FLOW" (registered trademark) manufactured by Nemoto Kyorindo Co., Ltd. can be used as the mixing device 312a.
  • a T-shaped connector can also be used instead of the mixing device 312a.
  • the needleless valve 313a is attached to the downstream end of the first main line 301a and is configured to open the flow path when a male luer lock connector is connected.
  • the first sub-line 301b connects the first container 40A and the first main line 301a.
  • the first sub-line 301b has a tube as a main component, and further has, in order from the first container 40A side, a spike 310b and a drip chamber 311b.
  • the spike 310b is connected to the first container 40A.
  • the downstream end of the first sub-line 301b is connected to a T-shaped tube 311a of the first main line 301a.
  • the first container 40A is, for example, a bottle-shaped container, and the contrast agent flowing out of the first container 40A is dripped into the drip chamber 312b and then supplied to the first main line 301a.
  • the T-shaped tube 311a is configured to prevent backflow of liquid from the first main line 301a to the first sub-line 301b and backflow of liquid from the downstream side to the upstream side of the first main line 301a.
  • backflow prevention can be achieved by appropriate means such as a check valve or a clamping mechanism that mechanically clamps the tube.
  • the second main line 302a has a tube as its main component, and further has, from the upstream side, a syringe connector 320a and a T-shaped tube 321a.
  • the syringe connector 320a is rotatably connected to the T-shaped tube 321a via a rotary joint, and the syringe 20B is detachably connected thereto.
  • the second sub-line 302b connects the second container 40B and the second main line 302a.
  • the second sub-line 302b has a tube as a main component, and further has, in order from the second container 40B side, a spike 320b and a drip chamber 321b.
  • the spike 320b is connected to the second container 40B.
  • the downstream end of the second sub-line 302b is connected to a T-shaped tube 321a of the second main line 302a.
  • the second container 40B is, for example, a bottle-shaped container, and the physiological saline solution flowing out of the second container 40B drips into the drip chamber 322b and is then supplied to the second main line 302a.
  • the T-shaped tube 321a is configured to prevent backflow of liquid from the second main line 302a to the second sub-line 302b and backflow of liquid from the downstream side to the upstream side of the second main line 302a.
  • backflow prevention can be achieved by appropriate means such as a check valve or a clamping mechanism that mechanically clamps the tube.
  • the subject line 303 has a tube as its main component, and further has, from the upstream side, a male luer lock connector 330, a flow path opening/closing valve 331, a check valve 332, and a male luer lock connector 333.
  • the male luer lock connector 330 is attached to the upstream end of the subject line 303, and is connected to the needleless valve 313a of the first main line 301a, thereby connecting the first main line 301a and the subject line 303.
  • the flow path opening and closing valve 331 is configured so that the flow path can be opened and closed arbitrarily by external operation.
  • a tube clamp mechanism that mechanically clamps the tube may be used instead of the flow path opening and closing valve 331.
  • the check valve 332 allows liquid to flow only in the direction from upstream to downstream.
  • the male luer lock connector 333 is attached to the downstream end of the subject line 303, and is connected to an injection needle assembly (not shown) having an injection needle that is inserted into the subject.
  • the flow passage opening and closing valve 331 may have the configuration shown in Figures 2A to 2C, for example.
  • the flow passage opening and closing valve 331 shown in the figure has a housing 501, a piston 502 inserted into the housing 501 so as to be slidable in the direction of the arrow S so as to be able to take an open position and a closed position, a top cap 503, and a bottom cap 504.
  • the housing 501 has a cylinder portion 501c into which the piston 502 is slidably inserted.
  • the cylinder portion 501c is formed of a through hole formed along the axial direction of the housing 501.
  • the housing 501 also has conduit portions 501a and 501b extending from the outer wall of the housing 501 in a direction perpendicular to the axial direction of the cylinder portion 501c adjacent to the cylinder portion 501c. Furthermore, the housing 501 is formed with a communication flow passage 501e that communicates the one conduit portion 501a and the cylinder portion 501c, and a communication flow passage 501g that communicates the other conduit portion 501b and the cylinder portion 501c. These conduit sections 501a, 501b and communication channels 501e, 501g are aligned in a straight line.
  • the piston 502 has a flange-shaped head 502a at one end that extends radially outward.
  • a flow path 502b is formed in the middle of the piston 502 in the longitudinal direction, crossing the piston 502 in a direction perpendicular to the longitudinal direction of the piston 502.
  • a neck portion 502c is formed, which has a smaller diameter than the part where the flow path 502b is formed and the head 502a.
  • Sealing rings 506 such as O-rings are attached to the outer circumferential surface of the piston 502 on both sides of the flow path 502b in the longitudinal direction of the piston 502.
  • the top cap 503 is attached to the end of the housing 501 on the side having the head 502a of the piston 502, thereby closing one open end of the cylinder portion 501c.
  • the bottom cap 504 is attached to the end of the housing 501 on the side opposite the top cap 503, thereby closing the other end of the cylinder portion 501c.
  • the piston 502 is inserted into the housing 501 with the head 502a protruding from the top cap 503. Therefore, in this embodiment, taking into consideration the ease of assembly of the flow path opening/closing valve 331, the top cap 503 is made up of two parts that are assembled from the side while the piston 502 is inserted into the housing 501.
  • the flow path opening/closing valve 331 has the top cap 503 and the bottom cap 504, it is possible to effectively prevent foreign matter from entering the inside of the flow path opening/closing valve 331.
  • the top cap 503 also has the function of limiting the amount of movement of the piston 502 in the direction in which the piston 502 is pulled out of the housing 501.
  • the bottom cap 504 also has the function of limiting the amount of movement of the piston 502 in the direction in which the piston 502 is pushed into the housing 501.
  • the flow passage 502b of the piston 502 is aligned in the same line as the communicating flow passages 501e and 501g of the housing 501, and the conduits 501a and 501b are connected via the flow passage 502b.
  • the inner surface of the housing 501 and the outer surface of the piston 502 are in contact at least in the closed position.
  • a gasket 507 can be added to the outer surface of the piston 502.
  • the piston 502 and the housing 501 can be made of materials with different elastic moduli. In this case, the gasket 507 is not necessary.
  • the housing 501 and the piston 502 are made of materials with different elastic moduli, for example, the housing can be made of polycarbonate (PC) and the piston can be made of high density polyethylene (HDPE).
  • the piston can be pushed into and pulled out of the housing 501 by using the head 502a.
  • an engagement member that engages with the head 502a and is operated to move back and forth in the direction of movement of the piston 502 can be engaged with the head 502a to move the piston 501 between the open position and the closed position.
  • the drug solution circuit 30 configured as described above can be divided into a single-use section 300A on the downstream side and a multiple-use section 300B on the upstream side.
  • the single-use section 300A is a section that can be used only once and is considered disposable.
  • the multiple-use section 300B is a section that can be used repeatedly multiple times. Specifically, the single-use section 300A is made up of the section downstream of the male luer lock connector 330, and the multiple-use section 300B is made up of the section upstream of the needleless valve 313a.
  • Single-use part 300A is replaced with a new one when the examination involving the injection of a drug solution and imaging of a subject is completed and the next subject is examined, whereas multiple-use part 300B is used as is until a predetermined number of examinations (e.g., five) are completed.
  • the connection part between single-use part 300A and multiple-use part 300B particularly male luer connector 330 and needleless valve 313a, are the parts that the user touches when replacing single-use part 300A.
  • male luer connector 330 has a cylindrical part that protrudes inside the rotary part connected to needleless valve 313a and is inserted to open needleless valve 313a.
  • the male luer connector 330 is structured so that the user does not touch the cylindrical portion when replacing the single-use part 300A. Therefore, in this embodiment, the male luer connector 330 is configured so that the tip of the cylindrical portion does not protrude beyond the rotary part. This maintains the cleanliness of the connection between the single-use part 300A and the multiple-use part 300B even when replacing the single-use part 300A, allowing the user to replace the single-use part 300A with peace of mind.
  • the needleless valve 313a is also similar in that there is a possibility that the user may touch it when replacing the single-use part 300A. Therefore, like the male luer connector 330, the needleless valve 313a is preferably configured so that the part into which the cylindrical part of the male luer connector 330 is inserted does not protrude from the housing part.
  • Air sensors 152, 432 detect air in specific parts of chemical liquid circuit 30, and chemical liquid circuit 30 may further include a silicone sleeve 341 corresponding to air sensors 152, 432. Silicon sleeve 341 is attached covering the tubes so as to be in close contact with air sensors 152, 432 when chemical liquid circuit 30 is attached to injection head 10a, thereby preventing erroneous detection of air due to poor contact between air sensors 152, 432 and the tubes.
  • the injection head 10a shown in FIG. 1 and its peripheral devices will be described.
  • the injection head 10a is supported on a stand 41 with casters via a flexible arm 42.
  • the injection head 10a can be connected to the flexible arm 42 via a swivel torque hinge so that the position of the injection head 10a does not change inadvertently.
  • the flexible arm 42 is supported on the stand with casters so as to be rotatable about the Z axis, and the syringes 20A and 20B (see FIG. 1) are detachably mounted on the injection head 10a.
  • the flexible arm 42 has a plurality of arms connected to each other and a spring for holding the positions of the arms, and is configured so that the injection head 10a can be held at any position in the X-Z plane without changing its position.
  • the X direction, Y direction, and Z direction shown in FIG. 3 correspond to the up-down direction, the left-right direction, and the front-rear direction, respectively.
  • the flexible arm 41 may further support at least one of a container holder 43 for holding a liquid container and a head display 44, which is an additional display device.
  • the head display 44 may have a light-emitting section 44a disposed on its upper edge.
  • the light-emitting section 44a is controlled to emit light, for example, so that it lights up during a self-check after the liquid injection device 10 is powered on and blinks during the liquid injection operation. This allows the user to easily recognize that the liquid injection device 10 is powered on and that the liquid injection device 10 is performing an injection operation, even from a position away from the injection head 10a.
  • the light-emitting section 44a emits light in a color that is easily recognized by the user, such as white or green.
  • injection head 10a has a syringe support assembly 120 that detachably supports syringes 20A, 20B, a motor-driven ball screw type linear actuator 130 that is arranged corresponding to each of syringes 20A, 20B for drawing medicinal liquid into each of syringes 20A, 20B and injecting medicinal liquid from each of syringes 20A, 20B, a needleless valve holding unit 140 that detachably holds needleless valve 313a and male luer lock connector 330 (see Figure 2) of chemical liquid circuit 30 in a connected state, and a flow path opening/closing valve holding unit 150 that detachably holds flow path opening/closing valve 331 (see Figure 2) of chemical liquid circuit 30.
  • the syringes 20A, 20B, the syringe support assembly 120, and the linear actuator 130 are covered by a housing 110 composed of a plurality of cover members.
  • the portions of the plurality of cover members that cover the syringes 20A, 20B in particular can be composed of syringe covers 110A, 110B that are supported by hinges 111 so as to be openable and closable for attaching and detaching the syringes 20A, 20B.
  • the portions of the syringe covers 110A, 110B that cover the syringes 20A, 20B are composed of a transparent material so that it is possible to visually check whether the syringes 20A, 20B are attached to the injection head 10a and the state of the syringes 20A, 20B attached to the injection head 10a.
  • the injection head 10a may also have a cover sensor 112 that detects whether the syringe covers 110A, 110B are closed.
  • the cover sensor 112 can be any sensor capable of detecting that the syringe covers 110A, 110B are closed, such as a mechanical switch or a proximity sensor.
  • the space inside the housing 110, covered by the syringe covers 110A and 110B, is configured to accommodate the syringes 20A and 20B as well as a portion of the multiple-use portion 300B (see FIG. 2) of the liquid medicine circuit 30 connected to the syringes 20A and 20B.
  • the portion of the multiple-use portion 300B is the first main line 301a, a portion of the first sub-line 301b, the second main line 302a, and a portion of the second sub-line 302b.
  • the multiple-use portion 300B of the liquid medicine circuit 30 is a portion that is used multiple times and for a relatively long period of time, it is hygienically preferable to configure the multiple-use portion 300B to be partially covered by the syringe covers 110A and 110B in this manner.
  • buttons 115 operated by the operator can be arranged on the top and/or side of the housing 110.
  • the group of buttons 115 includes a start button for starting the operation of the injection head 10a, such as the injection of a medicinal liquid, and a stop button for stopping the operation of the injection head 10a.
  • the group of buttons 115 has a plurality of A-side operation buttons 115A corresponding to the linear actuator 130 for operating the syringe 20A, and a plurality of B-side operation buttons 115B corresponding to the linear actuator 130 for operating the syringe 20B, so that the user can individually move each linear actuator 130 forward or backward as desired.
  • buttons are illuminated by a light-emitting source such as an LED (light-emitting diode) arranged in the housing 110, so that the buttons can be made to appear to emit light.
  • a light-emitting source such as an LED (light-emitting diode) arranged in the housing 110, so that the buttons can be made to appear to emit light.
  • the A-side operation button 115A and the B-side operation button 115B are illuminated in different colors, for example, the A-side operation button 115A is illuminated in green and the B-side operation button 115B is illuminated in blue, so that the user does not confuse which side the operation button is.
  • the button may be illuminated in a different color when it is being operated from when it is not being operated, for example, in white, so that the user can visually recognize that they are operating the button.
  • the syringe covers 110A, 110B may have rib-like portions 113 extending along the axial direction of the syringes 20A, 20B on the upper surface of each of the syringe covers 110A, 110B.
  • the rib-like portions 113 may be a part of the syringe covers 110A, 110B in which a part of the portion covering the syringes 20A, 20B is formed in a protruding shape, or may be composed of a separate part from the syringe covers 110A, 110B.
  • rear parts 114 of the syringe covers 110A, 110B adjacent to the button group 115 may be composed of a separate part from the portion covering the syringes 20A, 20B.
  • the rib-like portions 113 and rear parts 114 may be colored to correspond to the color of the light irradiating the A-side operation button 115A and the B-side operation button 115B, for example, green on the A side and blue on the B side.
  • rear portion 114 may have a plurality of linear protrusions extending in the axial direction of syringes 20A, 20B and arranged in parallel to each other.
  • Rib portion 113 and linear protrusions of rear portion 114 may function as an opening/closing assist structure that a user can hook their fingers on when opening covers 110A, 110B. Furthermore, linear protrusions of rib portion 113 and rear portion 114 may be made of a material that has a non-slip effect or may be given a non-slip function by applying a surface treatment that creates a non-slip effect.
  • the flow path opening/closing valve holding unit 150 is supported by an arm 171 so as to be positioned in front of the housing 110 and away from the housing 110.
  • the arm 171 is a highly rigid component, and is fixed to a strength member inside the housing 110, for example, the main body 121 of the syringe support assembly 120 (see FIG. 6A, etc.) described below.
  • the arm 171 is integrally provided with a handle portion 171a, and the user can grasp the handle portion 171a to change the orientation and move the injection head 10a up, down, left, and right.
  • the arm 171 has the effect of allowing the user to easily change the orientation and move the injection head 10a.
  • the injection head 10a is supported on the floor by a stand 41 with casters (see FIG. 3), but the injection head 10a may also be supported by being suspended from the ceiling by a ceiling-hanging arm mechanism (not shown).
  • the effect of the arm 171 is the same even when the injection head 10a is supported by a ceiling-suspended arm mechanism.
  • the arm 171 has high rigidity and is fixed to a strength member inside the housing 110, so that the user can change the orientation and move the injection head 10a as intended.
  • the arm 171 can be configured from metal or by covering a metal core with a resin cover material. When using a metal core, it is preferable to fix this core to a strength member inside the housing 110.
  • the handle portion 171a is preferably made of a material that is treated with an anti-slip coating and/or at least has a non-slip surface.
  • the arm 171 may be removably attached to the housing 110.
  • the flow path opening/closing valve holding unit 150 may be removably provided from the arm 171, and only the flow path opening/closing valve opening/closing unit 150 may be removable from the housing 110. In this manner, the flow path opening/closing valve holding unit 150 can be removed from the housing 110.
  • the flow path opening/closing valve opening/closing unit 150 can be removed, and a tube set whose distal end is branched into two can be connected to the syringes 20A and 20B as a drug solution circuit and used.
  • FIG. 4E is a plan view of the flow path opening/closing valve holding unit 150
  • Figure 4F is a plan view of the flow path opening/closing valve 331 removed.
  • the flow path opening/closing valve holding unit 150 has the above-mentioned drive mechanism 151 and air sensor 152.
  • a valve recess 153 for receiving the flow path opening/closing valve 331 is formed on the upper surface of the flow path opening/closing valve holding unit 150, and the flow path opening/closing valve 331 is fitted into this valve recess 153 so that it is detachably held in the flow path opening/closing valve holding unit 150.
  • the above-mentioned flow path opening/closing valve sensor 150a can be placed in this valve recess 153.
  • the valve recess 153 may be provided with an engagement claw 154 that elastically engages with the flow passage opening/closing valve 331.
  • the engagement claw 154 is formed to have an arc-shaped recess that receives the outer peripheral surface of the flow passage opening/closing valve 331 and protrudes from the valve recess 153.
  • the engagement claw 154 allows the flow passage opening/closing valve 150 to be held in the valve recess 153 by snap-fitting. As a result, the flow passage opening/closing valve 150 is held in a fixed position by the flow passage opening/closing valve holding unit 150, so that the operation of the drive mechanism 151 can be transmitted to the flow passage opening/closing valve 150 well.
  • the flow passage opening/closing valve 331 is held in the valve recess 153 by snap-fitting, the user can intuitively recognize that the flow passage opening/closing valve 331 is held in the valve recess 153.
  • a tube recess is formed to receive a tube that constitutes part of the subject line 303 (see FIG. 2) and is connected to the flow path opening/closing valve 331.
  • a plurality of protrusions 155 are arranged to hold the tube received in the tube recess from the side. These protrusions 155 are preferably arranged on both the upstream side and the downstream side of the flow path opening/closing valve 331.
  • a hook 156 is provided to hook the tube connected to the downstream side of the tubes connected to the flow path opening/closing valve 331.
  • the hook 156 is arranged at a position such that the air sensor 152 is located between the flow path opening/closing valve 150 and the hook 156.
  • the flow path opening/closing valve 331 is held in the tube recess with the tube fixed in position on the upstream side and downstream side of the flow path opening/closing valve 331. This allows the air sensor 152 to stably detect air.
  • the tube held in the tube recess can be easily removed from the tube recess and the flow path opening/closing valve 150 from the tube recess and the valve recess 153 by removing the tube from the hook 156 and pulling it up.
  • the flow path opening/closing valve 331 and the tube connected thereto constitute a part of the single-use part 300A that is replaced every time an inspection is performed, and the single-use part 300A is frequently attached and detached to and from the flow path opening/closing valve holding unit 150. Therefore, configuring the flow path opening/closing valve holding unit 150 so that the flow path opening/closing valve 150 and the tube can be easily attached and detached to and from the flow path opening/closing valve holding unit 150 as in this embodiment is particularly preferable in the drug injection device 10 that uses the single-use part 300A.
  • the flow path opening/closing valve 331 is held in the valve recess 153 by snap fit, so there is an extremely low possibility that the flow path opening/closing valve 331 will inadvertently come off from the valve recess 153. Moreover, even if the flow path opening/closing valve 331 comes off from the valve recess 153, this can be detected by the flow path opening/closing valve sensor 150a. Therefore, in this embodiment, the flow path opening/closing valve 331 can be operated with higher safety.
  • syringe 20 has a syringe outer cylinder 210 with an elliptical cross-sectional shape, a plunger (also called an aspirator or pusher) 220, and a gasket 230.
  • Syringe 20 is attached to injection head 10a with the major axis direction of the elliptical cross-section facing up and down (see FIG. 4B). This allows for a smaller dimension in the width direction (left-right direction) compared to a syringe of the same capacity with a circular cross-section, and therefore the width direction dimension of injection head 10a can be correspondingly reduced.
  • the plunger 220 is slidably inserted into the syringe barrel 210, and as shown in FIG. 5A, its rearmost position is located near the rear end of the syringe barrel 210.
  • the gasket 230 is formed of an elastic material, such as an elastomer or chlorinated butyl rubber, and is fitted into the tip of the plunger 220 and fixed to the plunger 220.
  • the gasket 230 also has an outer shape and size that allows it to slide together with the plunger 220 while sealing between the inner surface of the syringe barrel 210 and the outer surface of the gasket 230.
  • the syringe outer cylinder 210 has a nozzle portion 211 at the front end and a flange 212 at the rear end.
  • the flange 212 is located forward of the rear end of the syringe outer cylinder 210, so that the rear end surface 213 of the syringe outer cylinder 210 protrudes rearward from the flange 212.
  • a pair of notches 212a are formed on the outer peripheral surface of the flange 212.
  • the pair of notches 212a are located at both ends in the short axis direction of the elliptical cross section of the syringe outer cylinder 210. Also, as shown in FIG.
  • the rear end of the syringe outer cylinder 210 has an expanded diameter portion 210b whose radial opening dimension is larger than the radial opening dimension of the other portion that defines the inner surface 210a of the syringe outer cylinder 220.
  • a step D1 is generated between the inner surface 210a of the syringe outer cylinder 210 and the expanded diameter portion 210b.
  • the flange 212 is roughened, for example, by blasting treatment or the like. By roughening the flange 212, the syringe 20 is less likely to shift position when the syringe 20 is set in the injection head 10b and the medicinal liquid is injected at high pressure. Only the front surface of the flange 212 may be roughened, only the rear surface, or both surfaces.
  • the syringe outer cylinder 210 is filled with a medicinal liquid such as a contrast medium and saline.
  • the medicinal liquid may be prefilled by the manufacturer or may be filled at the medical site.
  • a syringe 20 prefilled with a medicinal liquid by the manufacturer is also called a prefilled syringe.
  • the nozzle portion 211 has a connector structure to which the syringe connector 310a or 320a (see FIG. 2) of the medicinal liquid circuit 30 is connected.
  • the medicinal liquid filled within the syringe outer cylinder 210 can be discharged outside the syringe outer cylinder 210, and by retracting the plunger 220 within the syringe outer cylinder 210, the medicinal liquid can be sucked into the syringe outer cylinder 210.
  • the material of the syringe outer cylinder 210 is not particularly limited, but examples include ZEONOR (registered trademark), Tritan (registered trademark), and Iupilon (registered trademark). Of these, Iupilon, which is biocompatible, is particularly preferred.
  • the plunger 220 has a plunger body 221 into which the gasket 230 is fitted, and a number of engagement claws formed on the rear surface of the plunger body 221.
  • the multiple engagement claws 222 are arranged at intervals in the circumferential direction of the plunger body 221, and the area surrounded by the multiple engagement claws 222 is a space centered on the center O of the plunger 220.
  • the center O of the plunger 220 is located on the central axis of the syringe outer cylinder 210 when the plunger 220 is inserted into the syringe outer cylinder 210.
  • the two engagement claws 222 are arranged at intervals from each other in the circumferential direction, in positions that are point-symmetrical with respect to the center O of the plunger 220.
  • the engagement claw 222 is configured to be elastically displaceable in directions toward and away from the center O of the plunger 220.
  • the engagement claw 222 has a leg portion 222a extending rearward from the rear surface 221a of the plunger body 221, and a displacement portion 222b extending further rearward and circumferentially from the leg portion 222a.
  • An outer protrusion 222c and an inner protrusion 222d extending circumferentially are formed on the outer peripheral surface and inner peripheral surface of the displacement portion 222b, respectively. The outer protrusion 222c and the inner protrusion 222d will be described in detail later.
  • the tip of plunger body 221 into which gasket 230 is fitted is shaped like an elliptical cone, and the shape of the inner surface of gasket 230 is complementary to the shape of the tip of plunger body 221.
  • the tip of plunger body 221 is cut, and the shape of the tip of plunger body 221 is shaped like an elliptical trapezoid. This creates a space between the tip surface of plunger body 221 and the inner surface of gasket 230.
  • FIG. 5F when plunger 220 is pushed into syringe outer cylinder 210 (see FIG.
  • gasket 230 deforms so as to compress the space between plunger body 221 and gasket 230 as the internal pressure generated in syringe outer cylinder 210 increases.
  • the radial dimension of the gasket 230 expands, improving the liquid-tightness between the gasket 230 and the inner peripheral surface of the syringe outer cylinder 210. This effectively prevents leakage of the medicinal liquid from the rear end of the syringe during the injection operation.
  • the distance TD from the tip surface of the plunger body 221 to the apex of the elliptical trapezoidal shape of the plunger body 221 is not particularly limited as long as it is a distance that causes the radial dimension of the gasket 230 to expand due to deformation of the gasket 230, but it is preferably in the range of 2 mm to 4 mm, and more preferably 3 mm.
  • the linear actuator 130 of this embodiment has a ball screw type drive mechanism including a casing composed of a cylindrical frame 131 and cap members 132 attached to both ends of the frame 131, and a rod 133 arranged inside the casing. Inside the casing, there are also arranged a ball screw rotated by a motor, a ball nut that meshes with the ball screw, and a guide rail that supports the ball nut so that it cannot rotate and is slidable relative to the ball screw.
  • the rod 133 is fixed to the ball nut, and when the ball screw is rotated by driving the motor, the rod 133 moves forward or backward together with the ball nut depending on the direction of rotation of the ball screw.
  • a presser 134 is attached to the front end of the rod 133.
  • a circumferential groove 134a is formed at the rear end of the presser 134, as shown in FIG. 6B.
  • the syringe support assembly 120 has a main body 121 attached to the front end of the linear actuator 130, a syringe receiver 122 fixed to the front surface of the main body 121, and a syringe presser 123 arranged within the main body 121, and is configured to support the syringe 20 by mounting the syringe 20 from above as shown by the white arrow in FIG. 6A.
  • the main body 121 is provided with a ball plunger 125.
  • the ball plunger 125 functions as an engagement structure arranged on both the left and right sides of the syringe presser 123 so as to engage with the notch 212a (see FIG.
  • the ball plunger 125 accurately positions the orientation of the syringe 20 around its axis.
  • the engagement structure that engages with the notch 212a of the flange 212 of the syringe 20 is not limited to the ball plunger 125, and any other means such as a leaf spring can be used as long as it provides a clicking sensation when engaged.
  • the syringe receiver 122 is formed with a flange receiving groove 122a (see Figures 6A and 6C) that is open at the top and that receives the flange 221 of the syringe outer cylinder 220 while guiding it, and the syringe 20 is supported by mounting the syringe 20 on the syringe support assembly 120 so that the flange 212 is positioned within this flange receiving groove 122a.
  • the syringe receiver 122 further has a syringe detection sensor 126 that detects whether the syringe 20 is mounted on the syringe support assembly 120.
  • the syringe detection sensor 126 can be any type of sensor, such as a mechanical sensor or an optical sensor. In this embodiment, a mechanical sensor is used that detects that the syringe 20 is mounted by contact with the syringe 20.
  • the syringe presser 123 presses the syringe 20 attached to the syringe support assembly 120 from behind, and in this embodiment is composed of a single member having a tapered front surface 123a.
  • the front surface 123a is designed with a shape and size that can block the opening at the rear end of the syringe outer tube 210 when the syringe 20 is attached to the syringe support assembly 120.
  • the front surface of the syringe presser 123 is elliptical in shape to match the syringe outer tube 210.
  • the front surface 123a of the syringe presser 123 is formed with an annular protrusion 123b having a shape and size that is positioned within the opening at the rear end of the syringe outer tube 210 when the syringe 20 is supported by the syringe support assembly 120.
  • the annular protrusion 123b is positioned inside the outer edge of the front surface 123a of the syringe presser 123.
  • the syringe holder 123 is supported on the main body 121 so as to be movable in the front-rear direction between the front end position and the rear end position. At the front end position, the front face 123a of the syringe holder 123 protrudes from the front face of the main body 121, and at least this protruding portion of the front face 123a of the syringe holder 123 is tapered.
  • each part of the syringe barrel 210 and the dimensions of each part of the syringe support assembly 120 are designed so that when the syringe 20 is attached to the syringe support assembly 120, the front face 123a of the syringe holder 123 abuts against the rear end face 213 of the syringe barrel 210 at an intermediate position between the front end position and the rear end position of the syringe holder 123.
  • the syringe support assembly 120 further has a coil spring 124, which is an elastic member disposed between the main body 121 and the housing of the linear actuator 130, and this coil spring 124 biases the syringe holder 123 forward so that it is located at the front end position.
  • the syringe holder 123 is further formed with a through hole 123c through which the presser 134 and rod 133 of the linear actuator 130 can pass.
  • the elastic member is not limited to the coil spring 124, and any member that biases the syringe holder 123 forward can be used.
  • the front surface 123a of the syringe holder 123 may be a flat surface as long as it can close the opening at the rear end of the syringe outer cylinder 210 when the syringe 20 is attached to the syringe support assembly 120.
  • the syringe holder 123 may also be made up of multiple parts.
  • the syringe holder 123 may be made up of two parts: a syringe holder main body and a plate attached to the front surface of the syringe holder main body.
  • the syringe holder main body and the plate have through holes formed therein through which the presser 134 and rod 133 of the linear actuator 130 can pass.
  • the syringe holder main body may be made of resin
  • the plate may be made of metal.
  • the plate may also be flat.
  • an appropriate packing is placed on the outer peripheral surface of the syringe holder 123 so as to maintain liquid-tightness between the syringe holder 123 and the main body 121. Furthermore, it is preferable that an appropriate packing is placed on the inner peripheral surface of the through hole 123c of the syringe holder 123 so as to maintain liquid-tightness between the syringe holder 123 and the presser 134. This makes it possible to prevent the medicinal liquid from entering the inside of the main body 121, for example, even if the medicinal liquid leaks from the rear end of the syringe during injection or adheres to the periphery of the syringe support assembly 120.
  • an appropriate packing is placed on the inner circumferential surface of the through hole of the cap member 132 of the linear actuator 130, through which the rod 133 is inserted, so as to maintain liquid-tightness with the rod 133. This prevents the liquid from penetrating further into the casing of the linear actuator 130, even if the liquid medicine enters the inside of the main body 121.
  • Various mechanical components for driving the linear actuator 130 are arranged inside the casing of the linear actuator 130, so preventing the liquid medicine from penetrating into the casing is particularly preferable from the viewpoint of preventing breakdown of the linear actuator 130.
  • the syringe 20 is attached to the syringe support assembly 120 by aligning the position of the flange 212 with the flange receiving groove 122a and pushing the syringe 20 downward.
  • the plunger 220 is in an initial position where the outer protrusion 222c formed on the outer peripheral surface of the displacement portion 222b of the engagement claw 222 is located at the enlarged diameter portion 210a at the rear end of the syringe outer barrel 210.
  • the rear end surface 213 of the syringe outer cylinder 210 first comes into contact with the portion of the syringe holder 123 that protrudes from the body 121 of the syringe support assembly 120.
  • the syringe outer cylinder 210 exerts a rearward force on the syringe holder 123, which moves it rearward against the biasing force of the coil spring 124.
  • the syringe 20 is further pushed down so that the portion of the flange 212 that should be received in the flange receiving groove 122a is received in the flange receiving groove 122a, thereby attaching the syringe 20 to the syringe support assembly 120.
  • FIG. 6E shows a cross-sectional view of the syringe 20 supported by the syringe support assembly 120.
  • the front surface 123a of the syringe holder 123 is in close contact with the rear end surface 213 of the syringe outer cylinder 210, and the opening at the rear end of the syringe outer cylinder 210 is blocked by the syringe holder 123. This prevents foreign matter from entering the inside of the syringe outer cylinder 210, and the inside of the syringe outer cylinder 210 can be kept clean.
  • a forward force is applied to the syringe outer cylinder 210 by the syringe holder 123 biased by the coil spring 124, and the front surface of the flange 212 of the syringe outer cylinder 210 is pressed against the inner wall on the front side of the flange receiving groove 122a. This allows the syringe 20 to be more reliably supported in a fixed state by the syringe support assembly 120.
  • annular protrusion 123b is formed on the front surface of the flange holder 123, so that when the syringe outer cylinder 210 passes over the annular protrusion 123b during the mounting operation of the syringe 20 to the syringe support assembly 120, the flange holder 123 moves backward once and then returns to its original position due to the biasing force of the coil spring 124.
  • This operation of the syringe holder 123 allows the operator to intuitively recognize that the syringe 20 is securely mounted to the syringe support assembly 120.
  • the annular protrusion 123b is located inside the opening on the rear end side of the syringe outer cylinder 210, the radial position of the syringe 20 relative to the syringe support assembly 120 is determined. In order to more effectively determine the radial position of the syringe 20, it is preferable that the annular protrusion 123b is formed in a position adjacent to the inner wall of the syringe outer cylinder 20 when the syringe 20 is mounted on the syringe support assembly 120.
  • the syringe support assembly 120 of this embodiment is configured so that the syringe 20 is fixed by pressing the syringe outer cylinder 210, whose flange 212 is received in the flange receiving groove 122a, from behind using the syringe presser 123, which is movable in the front-rear direction.
  • no movable mechanism such as a clamper for holding the syringe 20 is required, and the syringe support assembly 120 can be achieved with a simpler configuration. This contributes greatly to the miniaturization of the syringe support assembly 120, and further to the miniaturization of the injection head 10a.
  • the syringe 20 can be better held by combining it with a syringe 20 whose flange 212 is roughened.
  • the tip of the linear actuator 130 is composed of two parts, a rod 133 and a presser 134, so that if the shape of the syringe 20 attached to the injection head 10a, particularly the shape of the plunger 220, is changed, the presser 134 can be replaced with one that matches it.
  • the rod 133 and presser 134 can also be composed of a single part.
  • the syringe support assembly 120 to which the syringe 20 having an elliptical cross section is attached has been described, but there are also syringes 20 having circular cross sections, and the syringe support assembly 120 can also be configured to attach a syringe having a circular cross section. In that case, each part that constitutes the syringe support assembly 120 is modified to have a shape that fits the syringe having a circular cross section.
  • the presser 134 protrudes from the front surface 123a of the syringe retainer 123 and comes into contact with the plunger body 221 of the plunger 220 as shown in FIG. 7A.
  • the outer protrusion 222c of the engagement claw 222 of the plunger 220 rides from the enlarged diameter portion 210b to the inner surface 210a of the syringe outer cylinder 220 as shown in FIG. 7B.
  • the engaging claw 222 elastically deforms toward the center O of the plunger 222 (see FIG. 5D), and thereafter, as shown in FIG. 7C, the plunger 220 advances in conjunction with the advancement of the presser 134, with the engaging claw 222 remaining elastically deformed.
  • this operation is the medicinal liquid injection operation.
  • the circumferential groove 134a of the presser 134 is formed in a position facing the inner protrusion 222d when the outer protrusion 222c of the engagement claw 222 rides on the inner surface 210a of the syringe outer barrel 210, and the inner protrusion 222d of the engagement claw 222 engages with the circumferential groove 134a of the presser 134 as the engagement claw 222 elastically deforms. Therefore, as long as the engagement claw 222 is in an elastically deformed state, when the presser 134 is retracted, the plunger 220 retracts in conjunction with the retraction of the presser 134. This action when the syringe 20 is empty and connected to the liquid medicine circuit 30 (see FIG. 2) is the liquid medicine suction action.
  • the preferred dimensional relationship between the inner protrusion 222d and the circumferential groove 134a will be described with reference to FIG. 8.
  • the length L1 of the inner protrusion 222d in the front-rear direction is less than the length L2 of the circumferential groove 134a.
  • the front and rear corners of the tip portion of the inner protrusion 222d are formed with a curved surface (also called R processing), and for smoother engagement, it is more preferable that the radius R1 of the front corner is less than the radius R2 of the rear corner.
  • R1 and R2 is preferably expressed as the ratio of R1 to R2.
  • R1:R2 1:2 to 5, and for example, R1:R2 can be 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, or 1:5.
  • the depth D2 of the circumferential groove 134a is greater than the step D1 at the enlarged diameter portion 210b of the syringe barrel 210 (see FIG. 5B).
  • the plunger 220 is shown in which the two engaging claws 222 are arranged at a distance from each other in the circumferential direction in positions that are point symmetrical with respect to the center O.
  • the linear actuator 130 having a ball screw type drive mechanism
  • the rotational motion of the ball screw is converted into the linear motion of the presser 134, so if rotational wobble occurs in the ball screw, the wobble is also transmitted to the presser 134, and the presser 134 may move back and forth while wobbling.
  • the plunger 220 moves while the outer protrusion 222c of the engaging claw 222 is in contact with the inner surface 210a of the syringe outer cylinder 210, so that a sliding resistance acts between the outer protrusion 222c of the engaging claw 222 and the inner surface 210a of the syringe outer cylinder 210 when the plunger 220 moves.
  • the proportion of the engagement claws 222 surrounding the presser 134 in the circumferential direction is 70% or less, and more preferably 50% or less, so that the radial wobble of the presser 134 can be tolerated to a certain extent.
  • this proportion is preferably 30% or more.
  • the number and arrangement of the engaging claws 222 may be arbitrary. However, from the viewpoint of the inner protrusion 222d engaging with the circumferential groove 134a of the presser 134 in a balanced manner in the circumferential direction, it is preferable to arrange the engaging claws 222 at equal intervals in the circumferential direction. Also, from the viewpoint of suppressing the fluctuation of the motor current described above, it is preferable to arrange two engaging claws 222 at equal intervals in the circumferential direction.
  • the internal pressure generated when the drug solution is injected acts on the syringe outer cylinder 210 to deform the cross-sectional shape into a circle, that is, a force that shortens the length in the major axis direction and lengthens the length in the minor axis direction. Therefore, in order to allow the inner protrusion 222d of the engaging claw 222 to better engage with the circumferential groove 134a of the presser 134, it is preferable that the engaging claws 222 are arranged in a position that covers the major axis direction of the syringe 20.
  • the multiple engagement claws 222 are arranged at intervals in the circumferential direction, so that the user can visually check the state of engagement between the engagement claws 222 and the circumferential groove 134a of the presser 134 from between the engagement claws 222.
  • the engagement claws 222 may be located at a position where the user cannot visually check the state of engagement with the circumferential groove 134a of the presser 134. Therefore, it is preferable to appropriately design the arrangement of the engagement claws 222 according to the situation when the drug solution injection device 10 is used.
  • the engagement claws 222 when viewed from the rear end side of the syringe 20 with the syringe 20 attached to the injection head 10a, the engagement claws 222 are arranged at the upper left and lower right (see FIG. 5, etc.), but the engagement claws 222 may also be arranged at the upper right and lower left.
  • the needleless valve holding unit 140 has a lower cover 141 and an upper cover 142 supported on the lower cover 141 via a hinge so that it can be opened and closed.
  • the needleless valve holding unit 140 is located in front of one of the syringe covers 110A, straddling the inside and outside of the syringe cover 110A. This makes it possible to open the upper cover 142 when the one of the syringe covers 110A is closed, but to open the upper cover 142 when the syringe cover 110A is opened.
  • the needleless valve holding unit 140 holds the needleless valve 313a and the male luer lock connector 330 shown in FIG.
  • the lower cover 141 has a rotation stop structure for the needleless valve 313a, and the male luer lock connector 330 can be rotated to connect and disconnect with the needleless valve 313a even when the upper cover 142 is closed.
  • the needleless valve holding unit 140 is preferably configured to hold the entire needleless valve 313a without the needleless valve 313a protruding from the needleless valve holding unit 140 when the top cover 142 is closed. This allows the user to attach and detach the male luer connector 330 without touching the needleless valve 313a. This is preferable from the standpoint of maintaining the cleanliness of the needleless valve 313a.
  • the flow path opening/closing valve holding unit 150 is located in front of the injection head 10a and detachably holds the flow path opening/closing valve 331 of the liquid medicine circuit 20 shown in FIG. 2.
  • the flow path opening/closing valve holding unit 150 has a built-in drive mechanism 151 (see FIG. 2) controlled by the injection control unit 11 (see FIG. 1) for opening and closing the flow path opening/closing valve 331, and an air sensor 152 (see FIG. 2) for detecting air in the subject line 303 (see FIG. 2).
  • the air sensor 152 may be a sensor of any detection method, such as an ultrasonic air sensor.
  • the flow path opening/closing valve holding unit 150 further has a flow path opening/closing valve sensor 150a (see FIG. 2) for detecting that the flow path opening/closing valve 331 is held by the flow path opening/closing valve holding unit 150.
  • This flow path opening/closing valve sensor 150a may also be a sensor of any detection method.
  • the injection head 10a may further include a light-emitting unit that emits light to illuminate the space in the housing 110 in which the syringes 20A and 20B are attached.
  • the light-emitting unit will be described with reference to Figure 9, which is a perspective view of the main parts of the injection head 10a with the syringe covers 110A and 110B removed.
  • a lower case 111a constituting a part of the housing of the injection head 10a is disposed below the syringes 20A and 20B.
  • the light-emitting unit 160 can be disposed on the lower case 111a at a position corresponding to between the two syringes 20A and 20B.
  • the light-emitting unit 160 can have two light sources disposed on the left and right, and a light-shielding plate 111b that blocks light directed upward can be disposed above the light-emitting unit 160. This allows the two light sources to independently illuminate the two syringes 20A and 20B.
  • the two light sources may also emit light of different colors, such as blue and green. In this way, by illuminating the syringes 20A and 20B with the light-emitting unit 160, it becomes easier to visually check the remaining amount and state of the medicinal liquid in the syringes 20A and 20B (for example, the presence or absence of air bubbles).
  • LEDs can be used as the light source of the light-emitting unit 160.
  • an LED tape light in which multiple LEDs are arranged in a row can be used.
  • the LED tape light can be arranged along the longitudinal direction of the syringes 20A and 20B, so that the entire longitudinal direction of the syringes 20A and 20B can be illuminated with almost uniform brightness.
  • the light emission of the LED tape light can be controlled by the injection control unit 11 (see FIG.
  • the speed of the flow of light may be changed according to the moving speed of the presser 134.
  • the housing 110 is configured to accommodate a portion of the liquid medicine circuit 30, and is provided with a needleless valve holding unit 140 and a flow path opening/closing valve holding unit 150.
  • This configuration holds the main portion of the liquid medicine circuit 30 in the injection head 10a, and the liquid medicine circuit 20 is essentially mounted on the injection head 10a in a compactly assembled state.
  • mounting the liquid medicine circuit 30 on the injection head 10a prevents problems with handling the liquid medicine circuit 30, such as the tubes constituting the liquid medicine circuit 30 being inadvertently bent or the liquid medicine circuit 30 being inadvertently removed.
  • Container Holder 43 detachably holds containers 40A, 40B, and can be attached to injection head 10a via an appropriate bracket.
  • Container holder 43 will be described with reference to Figures 10A and 10B.
  • the container holder 43 has a housing that can receive two containers 40A, 40B in a downward position and that houses a part of the first sub-line 301b connected to the container 40A and a part of the second sub-line 302b connected to the container 40B.
  • a part of the housing is composed of an openable holder cover 430, and the first sub-line 301b and the second sub-line 302b housed therein can be attached and detached by opening the holder cover 430.
  • Inside the housing there can be an air sensor 432 that detects air in the first sub-line 301b and the second sub-line 302b, respectively.
  • the air sensor 432 any sensor such as an ultrasonic or optical air sensor can be used.
  • a heater (heater) for keeping the chemical solution housed in the containers 40A, 40B at a constant temperature may be provided in the housing.
  • the container holder 43 may also have a code reader 431 that reads bar codes (including two-dimensional codes) provided on the liquid containers 40A and 40B.
  • the bar codes record information about the liquid, such as the product code (specifically, the GTIN (Global Trade Item Number) of GS1), the type of liquid, the content, the manufacturer, the date of manufacture, the expiry date, the expiration date, the serial number, the serial code, the lot number, and, if the liquid is a contrast medium, the iodine concentration.
  • the information read by the code reader 431 can be appropriately processed by the injection control unit 11 (see FIG. 1).
  • the injection control unit 11 stores the above-mentioned product codes and images of the exterior including the labels attached to the containers of the liquids sold by each liquid manufacturer that can be used with the liquid injection device 10 as data.
  • the code reader 431 reads a barcode
  • the injection control unit 11 compares the read information with the stored data, and for a matching drug, can display at least a part of the read information and/or at least one of the stored images on at least the head display 44 out of the head display 44 and the display device 13 of the console 10b. This allows the user to know whether the barcode has been read correctly.
  • the information recorded in the barcode can be used to set the liquid injection protocol or to manage the liquid injection history, so it is important that the barcode is read correctly.
  • the container holder 43 may further include a container detection sensor (not shown) that detects that the liquid medicine containers 40A, 40B are attached to the container holder 43.
  • the container holder 43 may also include an indicator 435 that visually indicates that the liquid medicine containers 40A, 40B are attached to the container holder 43.
  • the indicator 435 may be configured to emit light by being irradiated by a light-emitting source such as an LED provided in the container holder 43.
  • the light-emitting state of the indicator 435 may be changed, for example, so that the indicator flashes when a barcode is read by the code reader 431, and lights up when a liquid medicine container is attached.
  • the indicator 435 may be arranged for only one of the liquid medicine containers. In that case, it is arranged on the side of the liquid medicine container filled with contrast medium.
  • the container holder 43 that fits the liquid medicine containers 40A and 40B, which are bottles, has been described.
  • liquid medicine containers include not only bottles but also bags (e.g., saline bags). Therefore, in order to hold the liquid medicine container even when the liquid medicine container is a bag, the container holder 43 may further have a bag holder that holds the bag by hanging it.
  • the bag holder 435 may have a pole 435a that extends vertically and is supported by the main body of the container holder 43, and a hook 435b attached to the upper end of the pole 435a, and the bag is hung on this hook 435b.
  • the pole 435a is preferably supported so as to be expandable and contractible in the vertical direction so as to accommodate bags of various sizes, and/or is preferably supported so as to be rotatable in the circumferential direction so as to hold the bag in various orientations.
  • the hook 435b is preferably attached to the pole 435a so as to be rotatable (see arrow) so as not to get in the way when not in use.
  • (C-3) Head Display Head display 44 is provided separately from display device 13 (see FIG. 1) provided in console 10b, and can be supported on injection head 10a via an appropriate bracket so that its orientation can be arbitrarily changed.
  • a touch panel display that allows input operations by the operator can be preferably used as head display 44.
  • Display 44 may display the same screen as display device 11, or a different screen. For example, at least a part of the information read by code reader 431 can be displayed on display 44.
  • the display screen on display 44 is controlled by injection control unit 11 (see FIG. 1).
  • FIGS. 11 to 24 show examples of screens displayed on the display (display device 13) and head display 44 provided in the console 10b.
  • FIG. 11 An imaging site selection screen as shown in Fig. 11 is displayed.
  • an image of a human body divided into a plurality of sections is displayed.
  • the imaging site can be specified by an appropriate input operation by the operator to select one of the plurality of sections.
  • a list screen of examination items corresponding to the specified imaging site is displayed as shown in Fig. 12.
  • the displayed examination items are registered in advance in the injection control unit 11 (see Fig. 1).
  • the examination item is set by selecting the examination item by an appropriate input operation by the operator.
  • the remaining amount of the medicinal liquid in the syringe may be displayed on the imaging site selection screen (Fig. 11) and the list screen of examination items (Fig. 12).
  • the injection condition setting screen may be displayed on both the display device 13 and the head display 44 of the console 10b, so that the injection conditions can be set from either the injection head 10a or the console 10b.
  • An example of the injection condition setting screen is shown in FIG. 13.
  • the injection condition setting screen can display the imaging site, the examination item, the subject's weight, the amount of iodine in the contrast agent to be injected, the volume of the attached syringe, the pressure limit value, the injection protocol of the liquid, and the like.
  • a heart rate monitor that measures the subject's heart rate is connected to the liquid injection device 10, the heart rate can also be displayed.
  • the injection protocol has a first phase in which the contrast agent is injected, a second phase in which the contrast agent is mixed with saline and injected, and a third phase in which saline is injected.
  • the injection speed, injection amount, and injection time of the liquid in each phase are also displayed.
  • the injection conditions can be registered in advance in the injection control unit 11 according to the examination item.
  • the numerical values can be changed arbitrarily by the operator as necessary.
  • a test bolus tab may be displayed on the injection condition setting screen.
  • a test bolus screen slides in as shown in FIG. 13B.
  • the test bolus screen that slides in may have a tab that includes a triangular mark, for example, and the user may operate the triangular mark to return the test bolus screen from the state shown in FIG. 13B where it slides in to the state shown in FIG. 13A, and the original injection condition setting screen may be displayed. This allows the user to perform intuitive operations.
  • the injection condition setting screen also displays an Air Check button, and when the user presses the Air Check button after confirming the injection conditions, an air check is performed.
  • the Air Check button is only displayed on the display device 13 of the console 10b.
  • the standby screen displays a "Start OK" button, for example, as shown in FIG. 14, and the liquid injection operation is performed when the operator performs a predetermined operation.
  • a frame line may be displayed around the periphery of the screen to clearly indicate to the operator that the setting of the injection conditions has been completed. If a frame line is displayed, it is preferable that the color of the frame line is different from the color of the main display area.
  • the standby screen may also be displayed on both the display device 13 and the head display 44 of the console 10b, so that the injection operation can be performed from either the injection head 10a or the console 10b.
  • FIG. 15 shows an example of an injection condition setting screen for an injection protocol different from that shown in FIG. 14.
  • the example shown in FIG. 15 has a first phase in which a contrast agent is injected, and a second phase in which saline is injected.
  • the type of medicinal liquid being injected for example, contrast medium or saline
  • the mixture ratio are also displayed along with the injection speed and injection volume of the medicinal liquid being injected, but it is also possible to display only the injection speed and injection volume.
  • FIGS. 16 to 21 show examples of an injection operation screen displayed during the injection operation of a medical fluid.
  • the injection operation screen can display a timeline and an injection protocol from the start of the injection operation.
  • the injection status at the current time is represented by an image such as a dot moving on the timeline with the passage of time.
  • the brightness of the image representing the timeline and the image representing the injection protocol may be changed before and after the current time, such as being displayed brightly before the current time and being displayed darkly after the current time.
  • the injection operation screen may display an imaging progress image showing the progress of exposure by the imaging device in conjunction with the start of the imaging operation by the imaging device. In the illustrated example, the imaging progress image is displayed below the timeline.
  • the injection pressure is measured or calculated using known techniques.
  • the display of an image showing the current injection status on a timeline may be changed to warn the operator visually or audibly. Changes to the image display may include increasing the size of the image, changing the color of the image, changing the image display pattern, etc., and one or more of these may be performed.
  • the set pressure limit value may be displayed on the injection operation screen, in which case the display of the pressure limit value may be changed when the measured or calculated injection pressure value reaches the pressure limit value.
  • a "Pressure Graph" tab may be displayed on the injection operation screen.
  • a pressure graph slides in as shown in FIG. 22B.
  • the screen returns to that shown in FIG. 22A. In this way, during the injection operation, the display of the injection protocol and the pressure graph may be switched depending on the user's operation.
  • the liquid injector can have a function of simulating a graph (TDC; Time Density Curve) showing how the CT value changes over time when liquid is injected under set injection conditions.
  • TDC Time Density Curve
  • a "Simulation" tab can be displayed on the injection condition setting screen, and the operator can select this "Simulation” tab to execute a function of simulating a TDC curve when liquid is injected under the injection conditions displayed on the injection condition setting screen.
  • Figs. 23 and 24 Examples of the simulation screen displayed when the simulation function is executed are shown in Figs. 23 and 24.
  • the simulation function is executed, first, as shown in Fig. 23, the simulation conditions are displayed together with an image that shows the part to be imaged in a schematic manner.
  • an "OK" button and a graph display button are also displayed on this simulation screen.
  • the graph display button is displayed as a graphic that resembles a graph.
  • the "OK" button is a button for returning to the screen shown in Fig. 23.
  • the graph display button can be represented by a graphic symbol that means a graph, and when the operator selects this graph display button, a simulated TDC graph as shown in Fig. 24 is displayed.
  • the TDC graph also shows a range that indicates the time for which a CT value equal to or greater than the target CT value is maintained.
  • the screen returns to that shown in Fig. 23.
  • route confirmation Prior to the injection of the medical fluid for contrast imaging, in order to confirm whether the injection route is established, route confirmation is performed in which physiological saline is injected at an injection speed and injection time that are slower than the injection speed and injection time of the medical fluid for contrast imaging. During route confirmation, a route confirmation screen can be displayed to confirm the injection conditions in route confirmation, etc.
  • a route confirmation (N.P. Test) call button is displayed on the injection condition setting screen (see FIG. 25) displayed on the head display 44.
  • the route confirmation screen displays the saline injection protocol (injection rate and injection amount) at the time of route confirmation, as shown in FIG. 26, for example.
  • the route confirmation screen may display a timeline showing the remaining amount of saline in the syringe and the elapsed time from the start of route confirmation.
  • a pressure glass showing the change in injection pressure of saline over time may be displayed in real time, as shown in FIG. 27, so that the user can visually check whether there is an abnormality in the injection route.
  • the route confirmation screens shown in FIG. 26 and FIG. 27 may display a close button, for example, indicated by an "x" mark, and the user may operate this close button to close the route confirmation screen and return to the display of the injection condition setting screen shown in FIG. 25. This allows the user to perform intuitive operations.
  • the display device 13 of the console 10b When the route confirmation call button is operated, the display device 13 of the console 10b also displays a route confirmation screen as shown in FIG. 28.
  • the route confirmation screen is displayed as a slide-in on the injection condition setting screen.
  • the route confirmation screen displayed on the display device 13 of the console 10b also displays an air check button.
  • the user presses the air check button after the injection conditions are confirmed an air check is performed and the system transitions to a standby state. In this state, the user performs a predetermined operation for performing route confirmation, and route confirmation is performed.
  • the route confirmation screen on the display device of the console 10b is also closed, and the display of the head display 44 and the display device 13 of the console 10b returns to the injection condition setting screen.
  • the route confirmation screen may be configured to have a tab including a triangular mark, and the user may operate the triangular mark portion to return the route confirmation screen from the slide-in display state to the state before the slide-in display. This allows the user to perform intuitive operations.
  • the syringe setting screen is displayed first.
  • a message urging the user to attach the syringe is displayed along with an OK button.
  • the syringe referred to here is an unused syringe, that is, a syringe that is not filled with medicinal liquid and whose plunger is located at the rearmost end. If the self-check detects that the presser is not at the rearmost end, the presser retraction screen is displayed.
  • a retraction button (displaying "Retract") is displayed along with an image of the syringe, and the presser is retracted when the user operates the retraction button. After the presser has been retracted, the syringe setting screen is displayed.
  • the screen transitions to a presser forward screen that prompts the user to press the presser forward button.
  • This screen also displays a start button, and when the user presses the start button, the presser forward movement begins, and at the same time, the screen transitions to a forward animation screen as shown in Figure 29.
  • the presser forward screen displays an animation of the plunger moving forward inside the syringe.
  • the forward animation screen also displays a stop button, and when the user presses the stop button, the screen returns to the presser forward screen.
  • the presser moves forward to the very front, the screen transitions to a multiple use part set screen that prompts the user to connect the multiple use part of the drug circuit.
  • This screen also displays an OK button, and when the user presses the OK button, the screen transitions to the filling screen.
  • FIG. 30 shows an example of a filling screen displayed on the head display 44.
  • a syringe image showing each of the syringes on the A side and the B side is displayed, along with a filling amount setting value arranged next to each syringe image.
  • the syringe image is animated according to the change in the amount of medicinal liquid in the syringe (actually the position of the linear actuator 130) during the filling operation.
  • a filling method setting button is displayed below the filling amount setting value.
  • "Full mode”, “Set mode” and “Add mode” are set as the filling method, and these modes are switched in sequence each time the button is operated.
  • “Full mode” the syringe is filled to its full capacity (150 mL in this embodiment).
  • Set mode it is filled until it reaches the set numerical value.
  • “Add mode” the amount of the set numerical value is filled. In any mode, when the amount filled in the syringe reaches its full capacity, the filling operation is stopped and no further filling is performed. Additionally, in “Set mode” and “Add mode,” a setting adjustment button is displayed next to the filling amount setting.
  • a warning pictogram is displayed above the fill amount setting value as necessary.
  • the warning pictogram is displayed when air is detected by air sensor 432 (FIG. 10B), that is, when air is detected in a portion of the liquid medicine circuit between the liquid medicine container and the syringe, and remains displayed until the air detection is released, at which point the filling operation is stopped.
  • the air detection may be released by replacing syringes 20A, 20B and multiple-use portion 300B of liquid medicine circuit 30, and filling multiple-use portion 300B with liquid medicine.
  • a start filling button is displayed below the syringe image.
  • the start filling button is displayed as an image resembling a downward arrow.
  • the amount of liquid remaining in the liquid container is displayed at the top of the filling screen.
  • the remaining amount of liquid is a value obtained by reading the barcode on the liquid container. As the liquid is filled, the remaining amount decreases. When the remaining amount of liquid reaches zero or a predetermined threshold, the filling operation is stopped. After the filling operation has stopped due to this, the liquid container can be replaced and the liquid can be refilled by performing the specified operation. When replacing the liquid container, the liquid container is removed and recognition of the liquid container is released, but at that point management of the remaining amount threshold is stopped and the remaining amount of liquid is not displayed. Note that on the filling screen shown in the figure, the remaining amount of liquid is only displayed for the contrast medium.
  • the user After the medicinal liquid filling operation is completed, the user operates the Next button to transition from the filling screen to the single-use unit setting screen.
  • the single-use unit setting screen displays a message prompting the user to connect the single-use unit 300A (see Figure 2) and an OK button.
  • the setup is complete.
  • the OK button When the OK button is operated, the screen transitions to the injection condition setting screen shown in Figure 25.
  • this injection condition setting screen displayed on the head display 44 shown in Fig. 25 will be described in more detail.
  • this injection condition setting screen displays the injection protocol (injection speed and injection amount of each liquid for each phase, elapsed time from the start of injection, etc.) and pressure limit value. These are displayed with the same values as the injection conditions set on the console 10b.
  • the injection condition setting screen displayed on the head display 44 displays an examination end button (displaying "Replace Multi-Use").
  • the screens displayed from the injection condition setting screen until the completion of the injection operation transition in conjunction with the screen on the display device 13 of the console 10b. That is, when the screen displayed on the display device 13 of the console 10b transitions to the standby screen under the specified conditions described above, the screen displayed on the head display 44 also transitions to the standby screen (see FIG. 31). Then, when the injection operation is started and the screen displayed on the display device 13 of the console 10b transitions to the injection screen, the screen displayed on the head display 44 also transitions to the injection screen (see FIG. 32).
  • the injection screen displays "Inj. Comp.”, which means that the injection is complete, to notify the user that the injection is complete, and also displays a message urging the user to replace the single-use unit 300A.
  • the injection protocol display also goes dark, which also allows the user to visually recognize that the injection operation is complete. This type of screen change is also seen on the injection screen displayed on the display device 13 of the console 10b.
  • the screen transitions to the single-use unit setup screen described above. Meanwhile, the screen displayed on the display device 13 of the console 10b transitions to the imaging site selection screen (see FIG. 11).
  • the single-use unit 300A is set up according to the screen displayed on the display device 13 of the console 10b and the screen displayed on the head display 44, and the series of procedures for setting the injection conditions is repeated.
  • the single-use section setup screen displayed on the head display 44 also displays an end of examination button (displaying "Exam. End"), and when the user operates the end of examination button at this stage or during the injection condition setting stage, the screen displayed on the head display 44 transitions to the end of examination screen.
  • the examination end screen displays an examination end button (displaying "Exam. End") and a multiple-use part replacement button (displaying "Replace Multi-Use").
  • the examination end button When the examination end button is operated, the screen transitions to the presser retraction screen described above (see setup explanation) so that the multiple-use part 300B and syringe can be removed, and after the presser retracts, guidance is displayed encouraging the user to turn off the power.
  • the multiple-use part replacement button the screen transitions to the presser retraction screen, and after the presser retracts, setup for the next examination begins.
  • the injection control unit 11 (see FIG. 1) counts the number of tests since the multiple-use unit 300B is connected and displays the count as the number of uses of the multiple-use unit 300B on the head display 44 and/or the display device 13 of the console 10b.
  • the screen that displays the number of uses of the multiple-use unit 300B can be, for example, a screen for setting up the next test after the test is completed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention permet à un utilisateur de déterminer facilement l'état d'un système d'injection de solution chimique. Ce système d'injection de solution chimique comprend une tête d'injection 10a, un dispositif d'affichage 13 et une unité de commande d'injection 11 qui commande le fonctionnement de la tête d'injection 10a et de l'affichage sur le dispositif d'affichage 13. L'unité de commande d'injection 11 surveille la pression d'injection pendant l'opération d'injection de solution chimique. En outre, l'unité de commande d'injection 11 est conçue pour afficher, pendant l'opération d'injection de solution chimique, un écran qui présente une ligne de temps représentant le passage du temps et une image représentant le moment présent dans le temps sur la ligne de temps, et pour changer l'affichage de l'image lorsque la pression d'injection surveillée atteint une valeur limite de pression d'injection définie à l'avance.
PCT/JP2023/042433 2022-11-25 2023-11-27 Système d'injection de solution chimique WO2024111676A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-188786 2022-11-25
JP2022188786 2022-11-25

Publications (1)

Publication Number Publication Date
WO2024111676A1 true WO2024111676A1 (fr) 2024-05-30

Family

ID=91196225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/042433 WO2024111676A1 (fr) 2022-11-25 2023-11-27 Système d'injection de solution chimique

Country Status (1)

Country Link
WO (1) WO2024111676A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105577A1 (fr) * 2011-02-01 2012-08-09 株式会社根本杏林堂 Dispositif d'injection de solution de médicament
WO2016084940A1 (fr) * 2014-11-28 2016-06-02 株式会社根本杏林堂 Dispositif d'injection de solution de médicament
WO2020231506A1 (fr) * 2019-05-16 2020-11-19 Milestone Scientific, Inc. Dispositif et méthode d'identification d'une région cible

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105577A1 (fr) * 2011-02-01 2012-08-09 株式会社根本杏林堂 Dispositif d'injection de solution de médicament
WO2016084940A1 (fr) * 2014-11-28 2016-06-02 株式会社根本杏林堂 Dispositif d'injection de solution de médicament
WO2020231506A1 (fr) * 2019-05-16 2020-11-19 Milestone Scientific, Inc. Dispositif et méthode d'identification d'une région cible

Similar Documents

Publication Publication Date Title
JP6689930B2 (ja) 薬液注入装置および薬液注入システム
EP1847284B2 (fr) Système d'injecteur
US6752789B2 (en) Syringe plunger locking mechanism
JP4769196B2 (ja) コントローラ装置
WO2017038575A1 (fr) Circuit d'injection de liquide médicamenteux, système d'injection de liquide médicamenteux doté dudit circuit d'injection de liquide médicamenteux et système d'imagerie médicale
US20200030524A1 (en) Chemical liquid injector
US11633544B2 (en) Injection head and chemical injection device comprising same
JP2018167058A (ja) 薬液回路およびそれを使用する薬液回路システム
US20230115595A1 (en) Intravenous infusion pump with cassette insertion and pump control user interface
WO2024111676A1 (fr) Système d'injection de solution chimique
WO2024111675A1 (fr) Système d'injection de solution de médicament
JP7500441B2 (ja) 薬液回路用開閉ユニット駆動機構および薬液注入装置
WO2023199993A1 (fr) Dispositif d'injection de liquide médical
WO2020158809A1 (fr) Dispositif d'injection de médicament liquide pour angiogramme
JP2018202035A (ja) 留置針、及び医療用コネクタ器具

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23894678

Country of ref document: EP

Kind code of ref document: A1